2014, Number 3
PDF size: 200.65 Kb.
ABSTRACTIntroduction: studies are available about the differences between reversal of neuromuscular blockers with sugammadex and neostigmine. Most studies agree that results are better when sugammadex is used.
Objectives: compare the capacity of sugammadex and neostigmine to revert vecuronium-induced neuromuscular blockade.
Methods: a case-control study was conducted to evaluate neuromuscular recovery with vecuronium after reversal with sugammadex and neostigmine. Muscular recovery was evaluated by clinical examination.
Results: a total 405 patients were studied. Group S was composed of 135 patients and Group N of 270. Mean surgical duration was 32.21±1.2 min for Group S and 33.16±1.2 min for Group N. Average reversal time was 2.2 min in Group S and 14.4 min in Group N. The quality of recovery was good in both groups. However, the frequency differences found in patients reverted with sugammadex were statistically significant (p = 0.00001). Complications were more frequent in Group N.
Conclusions: the capacity of sugammadex to revert vecuronium-induced neuromuscular blockade was confirmed. Reversal time was 6.54 longer with neostigmine. The quality of recovery was 1.34 times better with sugammadex. Adverse reactions were 11.02 times more frequent with neostigmine than with sugammadex.
Cordero Escobar I, Rey Martínez B, Company Teuler R, Pérez Carbonell A. Reversión del rocuronio con sugammadex en pacientes con procederes de larga duración. Presentación de dos casos. Rev Cubana Anest Rean 2011; 10 (2): En línea. [Consultado: 5/52011]. URL disponible en: http://bvs.sld.cu/revistas/scar/indice.html
Ohshita N, Tsutsumi YM, Kasai A, Soga T, Kanamura T, Katayama T, Iseki A, Tomiyama Y, Tanaka K. Two cases of anaphylactoid reaction after administration of sugammadex. Masui 2012;61(11):1261-4. de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30(9):599-611.